Artesunate

Indications

  • Plasmodium Falciparum Malaria (see Malaria, [[Malaria]]): meeting any of the following criteria
    • High Level of Parasitemia
    • Inability to Tolerate Oral Medications
    • Lack of Timely Access to Intravenous Quinidine
    • Quinidine Intolerance
    • Quinidine Failure
    • Severe Malaria

Pharmacology

  • Artemisinin Derivative: potent inhibition of Plasmodium Falciparum exported protein 1 (EXP1), which is a membrane glutathione S-transferase
    • Artemisinins are derivatives from the “quinghaosu” (sweet wormwood) plant, Artemisia annua

Administration

  • Available on Compassionate Use from CDC: not licensed for use in the US
  • IV

Adverse Effects

Hematologic Adverse Effects

  • Decreased Reticulocyte Count
  • Delayed Hemolytic Anemia (see Hemolytic Anemia, [[Hemolytic Anemia]])
    • Occurs 2-3 wks after treatment
    • Unclear if this is due to the drug or to the malaria itself

Other Adverse Effects

  • xxx

References

  • xxx